Spatial pharmacometabolomic profiling of two antipsychotics reveals region-specific neurochemical alterations in the rat brain
4 affiliations
- 1Department of Pharmaceutical Biosciences, Spatial Mass Spectrometry, Uppsala University, Uppsala, SE-75124, Sweden
- 2Department of Pharmacy, Translational PKPD Research Group, Uppsala University, Uppsala, SE-75123, Sweden
- 3Department of Pharmaceutical Biosciences, Spatial Mass Spectrometry, Uppsala University, Uppsala, SE-75124, Sweden; Spatial Mass Spectrometry, Science for Life Laboratory, Uppsala University, Uppsala, SE-75124, Sweden
- 4Department of Pharmaceutical Biosciences, Spatial Mass Spectrometry, Uppsala University, Uppsala, SE-75124, Sweden; Corresponding author.
Abstract
Defining how antipsychotic drugs acutely reshape neurochemical signaling across discrete brain regions is critical for understanding their central pharmacological actions. Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) enables spatially resolved, untargeted molecular profiling directly in tissue and is well suited to investigate early drug-induced effects. Here, we applied MALDI-MSI to characterize acute neurochemical and metabolomic alterations and to explore trypsin-digested peptidomic changes in rat brain following single-dose exposure to the atypical antipsychotics risperidone and olanzapine. By using MALDI matrices optimized for neurotransmitters, small metabolites, and peptides, we achieved broad molecular coverage across cortical, striatal, and hippocampal regions. This approach revealed distinct, drug-specific spatial signatures encompassing monoamine-related metabolites, purine metabolism, and lipids. In the striatum, both compounds altered dopamine metabolism, as reflected by changes in 3-methoxytyramine, 3,4-dihydroxyphenylacetic acid, and homovanillic acid. In cortical and hippocampal regions, risperidone selectively increased levels of the norepinephrine metabolite 3-methoxy-4-hydroxyphenylethyleneglycol sulfate, indicating a distinct noradrenergic signature. Pathway analysis identified purine metabolism as a major treatment-responsive pathway, consistent with altered nucleotide homeostasis and energy metabolism. Together, these findings provide spatially resolved insight into how atypical antipsychotics modulate brain chemistry, revealing region-specific neurochemical signatures underlying their pharmacological effects.
Related
- Refined Four-Layer Peripapillary OCTA Enables Layer-Specific Localization of Microvascular Alterations in Retinal Vein Occlusion
- Ultra-sensitive Mapping of Cell-free DNA-derived Methylomes Reveals Brain-specific Epigenetic Alterations Implicated in Alzheimer Disease
- Integrated multi-omics profiling identifies ECM-associated and systemic metabolic alterations associated with osteosarcoma metastasis
- Cross‐Organ Multi‐Omics Profiling of Systemic Alterations in 5xFAD Mice and Changes Associated with Huanglian Jiedu Decoction Treatment
- Multi-omics profiling reveals epigenetic alterations and a candidate SIRT1-β-catenin axis in bakuchiol ferulate-mediated photoaging protection
BibTeX
@article{lee2026spatial,
title = {{Spatial pharmacometabolomic profiling of two antipsychotics reveals region-specific neurochemical alterations in the rat brain}},
author = {Yea-Rin Lee and Nivetha Dayanidhi and Irena Loryan and Margareta Hammarlund-Udenaes and Reza Shariatgorji and Anna Nilsson and Per E. Andrén and Theodosia Vallianatou},
journal = {Neurotherapeutics},
year = {2026},
month = oct,
doi = {10.1016/j.neurot.2026.e01101},
url = {https://doi.org/10.1016/j.neurot.2026.e01101},
note = {CC BY},
}
RIS
TY - JOUR
TI - Spatial pharmacometabolomic profiling of two antipsychotics reveals region-specific neurochemical alterations in the rat brain
AU - Yea-Rin Lee
AU - Nivetha Dayanidhi
AU - Irena Loryan
AU - Margareta Hammarlund-Udenaes
AU - Reza Shariatgorji
AU - Anna Nilsson
AU - Per E. Andrén
AU - Theodosia Vallianatou
PY - 2026
DA - 2026/10/22
JO - Neurotherapeutics
DO - 10.1016/j.neurot.2026.e01101
UR - https://doi.org/10.1016/j.neurot.2026.e01101
AB - Defining how antipsychotic drugs acutely reshape neurochemical signaling across discrete brain regions is critical for understanding their central pharmacological actions. Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) enables spatially resolved, untargeted molecular profiling directly in tissue and is well suited to investigate early drug-induced effects. Here, we applied MALDI-MSI to characterize acute neurochemical and metabolomic alterations and to explore trypsin-digested peptidomic changes in rat brain following single-dose exposure to the atypical antipsychotics risperidone and olanzapine. By using MALDI matrices optimized for neurotransmitters, small metabolites, and peptides, we achieved broad molecular coverage across cortical, striatal, and hippocampal regions. This approach revealed distinct, drug-specific spatial signatures encompassing monoamine-related metabolites, purine metabolism, and lipids. In the striatum, both compounds altered dopamine metabolism, as reflected by changes in 3-methoxytyramine, 3,4-dihydroxyphenylacetic acid, and homovanillic acid. In cortical and hippocampal regions, risperidone selectively increased levels of the norepinephrine metabolite 3-methoxy-4-hydroxyphenylethyleneglycol sulfate, indicating a distinct noradrenergic signature. Pathway analysis identified purine metabolism as a major treatment-responsive pathway, consistent with altered nucleotide homeostasis and energy metabolism. Together, these findings provide spatially resolved insight into how atypical antipsychotics modulate brain chemistry, revealing region-specific neurochemical signatures underlying their pharmacological effects.
SN - 1878-7479
SN - 1933-7213
ER -